Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
133 hedge funds and large institutions have $1.34B invested in Apellis Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 50 increasing their positions, 37 reducing their positions, and 24 closing their positions.
38% more capital invested
Capital invested by funds: $973M → $1.34B (+$371M)
38% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 24
35% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 37
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
19% more call options, than puts
Call options by funds: $43.1M | Put options by funds: $36M
5.29% more ownership
Funds ownership: 63.4% → 68.69% (+5.3%)
3% more funds holding
Funds holding: 129 → 133 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$30.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$20.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$19M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$15.4M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$58.9M |
| 2 |
O
OrbiMed
New York
|
-$15M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$15M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$11.1M |
| 5 |
Morgan Stanley
New York
|
-$8.01M |
APLS Hedge Fund Activity: Q4 2019 in Review
133 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q4 2019, worth a combined $1.34B — up 38% from $973M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new APLS positions and 24 closed out — a net gain of 9 holders — while 50 added to existing stakes and 37 trimmed.
The largest buyer was Barclays, adding an estimated $30.8M. The largest seller was Millennium Management, cutting an estimated $58.9M.
- 133 institutional investors held Apellis Pharmaceuticals (APLS) as of Q4 2019, up from 129 in Q3 2019.
- Funds reported $1.34B of Apellis Pharmaceuticals stock for Q4 2019, up 38% quarter-over-quarter.
- 33 funds opened new Apellis Pharmaceuticals positions in Q4 2019 and 24 closed out, a net change of +9 holders.
- The largest Apellis Pharmaceuticals buyer in Q4 2019 was Barclays, an estimated $30.8M added.
- The largest Apellis Pharmaceuticals seller in Q4 2019 was Millennium Management, an estimated $58.9M sold.
Based on aggregated 13F filings for Q4 2019.